Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Ritonavir
ABBVIE PTE. LTD.
J05AE03
100.0 mg
TABLET, FILM COATED
Ritonavir 100.0 mg
ORAL
Prescription Only
AbbVie Deutschland GmbH & Co. KG
ACTIVE
2013-01-15
Page 1 of 19 NORVIR® (ritonavir tablets) (ritonavir capsules) (ritonavir oral solution) WARNING CO-ADMINISTRATION OF NORVIR WITH CERTAIN NONSEDATING ANTIHISTAMINES, SEDATIVE HYPNOTICS, ANTIARRHYTHMICS, OR ERGOT ALKALOID PREPARATIONS MAY RESULT IN POTENTIALLY SERIOUS AND/OR LIFE-THREATENING ADVERSE EVENTS DUE TO POSSIBLE EFFECTS OF NORVIR ON THE HEPATIC METABOLISM OF CERTAIN DRUGS. SEE CONTRAINDICATIONS AND PRECAUTIONS SECTIONS. DESCRIPTION Ritonavir is an inhibitor of HIV protease with activity against the Human Immunodeficiency Virus (HIV). Ritonavir is a white to light tan powder and has a bitter metallic taste. It is freely soluble in methanol and ethanol, soluble in isopropanol and practically insoluble in water. Ritonavir is chemically designated 10-Hydroxy-2-methyl-5-(1-methylethyl)1-[2-(1-methylethyl) -4-thiazolyl]- 3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S- (5R*,8R*,10R*,11R*)]. Its molecular formula is C 37 H 48 N 6 O 5 S 2 and molecular weight is 720.95. Ritonavir has the following structure: Ritonavir is supplied as a film coated tablet, oral solution and as a soft gelatin capsule. Ritonavir film coated tablets are available for oral administration in a strength of 100 mg with the following inactive ingredients: copovidone, dibasic calcium phosphate anhydrous / calcium hydrogen phosphate anhydrous, sorbitan monolaurate, colloidal silicon dioxide / colloidal anhydrous silica and sodium stearyl fumarate. The following are the ingredients in the film coating: hypromellose, titanium dioxide E171, polyethylene glycol 400 / macrogol type 400, hydroxylpropyl cellulose, talc, polyethylene glycol 3350 / macrogol type 3350, colloidal silicon dioxide / colloidal silica anhydrous and polysorbate 80. Ri Read the complete document
Page 1 of 19 NORVIR® (ritonavir tablets) WARNING CO-ADMINISTRATION OF NORVIR WITH CERTAIN NONSEDATING ANTIHISTAMINES, SEDATIVE HYPNOTICS, ANTIARRHYTHMICS, OR ERGOT ALKALOID PREPARATIONS MAY RESULT IN POTENTIALLY SERIOUS AND/OR LIFE-THREATENING ADVERSE EVENTS DUE TO POSSIBLE EFFECTS OF NORVIR ON THE HEPATIC METABOLISM OF CERTAIN DRUGS. SEE CONTRAINDICATIONS AND PRECAUTIONS SECTIONS. DESCRIPTION Ritonavir is an inhibitor of HIV protease with activity against the Human Immunodeficiency Virus (HIV). Ritonavir is a white to light tan powder and has a bitter metallic taste. It is freely soluble in methanol and ethanol, soluble in isopropanol and practically insoluble in water. Ritonavir is chemically designated 10-Hydroxy-2-methyl-5-(1-methylethyl)1-[2-(1-methylethyl) -4-thiazolyl]- 3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S- (5R*,8R*,10R*,11R*)]. Its molecular formula is C 37 H 48 N 6 O 5 S 2 and molecular weight is 720.95. Ritonavir has the following structure: Ritonavir is supplied as a film coated tablet. Ritonavir film coated tablets are available for oral administration in a strength of 100 mg with the following inactive ingredients: copovidone, dibasic calcium phosphate anhydrous / calcium hydrogen phosphate anhydrous, sorbitan monolaurate, colloidal silicon dioxide / colloidal anhydrous silica and sodium stearyl fumarate. The following are the ingredients in the film coating: hypromellose, titanium dioxide E171, polyethylene glycol 400 / macrogol type 400, hydroxylpropyl cellulose, talc, polyethylene glycol 3350 / macrogol type 3350, colloidal silicon dioxide / colloidal silica anhydrous and polysorbate 80. CLINICAL PHARMACOLOGY _MECHANISM OF ACTION_ Ritonavir is an orally active peptidomimetic inhibitor of the HIV-1 and HIV-2 aspartyl proteases. Inhibition of HIV protease renders the enzyme incapable of processing the gag-pol polyprotein precursor which leads to the production of HIV particles with immature morphology that are unable to initiate new ro Read the complete document